A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
Clinical trial NCT02924688 · COMPLETED
Trial details
- NCT number
- NCT02924688
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-13
- Primary completion
- 2019-02-22
- Enrollment
- 2436
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.